Citius Pharmaceuticals (CTXR) to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company

Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company

IPO with distribution of shares to Citius shareholders planned for 2H 2022

Citius would retain Mino-Lok and other pipeline assets and continue to trade on Nasdaq (ticker: CTXR)

CRANFORD, N.J., May 25, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it intends to split the Company's assets into two separate publicly-traded... More